This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Johnson & Johnson (JNJ) Stock Moves -0.19%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $159.02, marking a -0.19% move from the previous day.
Top Stock Reports for Johnson & Johnson, UnitedHealth & Comcast
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), UnitedHealth Group (UNH), and Comcast (CMCSA).
J&J ETFs to Shine Bright as FDA Grants EUA for Coronavirus Vaccine
by Sweta Jaiswal, FRM
Johnson & Johnson's receipt of EUA for its single-shot COVID-19 vaccine will strengthen the U.S. government's position in the fight against the pandemic and benefit ETFs with high exposure to the pharmaceutical giant.
6 Red-Hot ETFs of February
by Sweta Killa
We have highlighted some equity ETFs that gained immense popularity last month and will likely to do so, given the encouraging development in vaccines from likes of Johnson & Johnson (JNJ) as well as upbeat manufacturing and consumer spending data.
Wall Street Starts a Fresh Week at Record Highs
by Zacks Equity Research
Wall Street Starts a Fresh Week at Record Highs
Merck to Assist J&J Vaccine; Target Beats in Q4
by Mark Vickery
Merck will assist in the manufacture of J&J's just-released Covid-19 vaccine. Specific details are still forthcoming.
Stocks Off to a Solid Start in March: 6 Bargain ETF Picks
by Sweta Killa
Given the jump in investors' sentiment, ETFs that still trade at bargain price seem excellent pick.
5 Stocks to Buy Amid Continued Expansion in Manufacturing
by Kaustav Ghosh
The U.S. manufacturing sector continues to expand after the COVID-induced slump early last year, making it wise to look at names like ACM Research (ACMR), EnPro Industries (NPO) and iRobot (IRBT).
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
ETF Strategies to Gain From the Stimulus & Vaccine Optimism
by Sweta Jaiswal, FRM
Let's look at some ETF strategies to help investors gain from optimism surrounding another trench of coronavirus-aid package and coronavirus vaccine development.
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Interest Rate Jitters Weigh on US Equities
by David Borun
Anticipation of increased government borrowing send yields higher and stocks lower.
How to Trade USFDA's EUA to J&J Vaccine With ETFs
by Sanghamitra Saha
On Feb 27, the United States sanctioned Johnson & Johnson's COVID-19 vaccine for emergency use, giving the nation a third vaccine to fight the outbreak, after BioNTech/Pfizer and Moderna.
FDA Emergency Nod for J&J COVID-19 Vaccine Heats Up Competition
by Kinjel Shah
J&J's (JNJ) single shot COVID-19 vaccine gets FDA emergency use authorization. U.S. CDC Advisory Committee also recommends J&J's vaccine.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Will ETFs Rally as US Consumer Confidence Improves in February?
by Sweta Jaiswal, FRM
The moderate improvement in consumer confidence is likely to boost the consumer discretionary sector, which attracts a major portion of consumer spending.
FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses
by Zacks Equity Research
FATE reports a wider Q4 loss on increased R&D expenses.
Stock Market News for Feb 25, 2021
by Zacks Equity Research
U.S. stock markets closed higher on Wednesday after further positive comments from the U.S. Federal Reserve Chair eased concerns on inflation
7 Blue-Chip Stocks to Buy as Dow Touches a New Milestone
by Nalak Das
We have narrowed our search to seven Dow stocks with strong growth potential for 2021. These are: GS, CAT, JNJ, AAPL, MSFT, TRV and DOW.
Zacks Market Edge Highlights: Walgreens Boots, Johnson & Johnson, Chipotle, Lululemon and XLK
by Zacks Equity Research
Zacks Market Edge Highlights: Walgreens Boots, Johnson & Johnson, Chipotle, Lululemon and XLK
How to Create a Stock Portfolio
by Tracey Ryniec
You want to buy stocks. But how do you create a portfolio?
Consumer Confidence For February Came In Better-Than-Expected
by Zacks Equity Research
Consumer Confidence For February Came In Better-Than-Expected
Theravance (TBPH) Q4 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Theravance's (TBPH) loss narrows in the fourth quarter of 2020 while revenues meet the consensus estimate.
J&J Vaccine Looks Ready for EUA; Lowe's (LOW) Beats in Q4
by Mark Vickery
Following an important advisor meeting this Friday, it is widely expected an EUA will be forthcoming for Johnson & Johnson's (JNJ) vaccine as early as this weekend.
Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls
by Zacks Equity Research
Halozyme (HALO) reports lower-than-expected fourth-quarter earnings. However, revenues beat estimates. The company's outlook for 2021 is below market expectations.